Weight Loss Injections UK 2026: Mounjaro vs Wegovy vs Ozempic Compared

Originally published 2025 · Updated April 2026 with new research including MHRA approval of Wegovy 7.2mg and the latest Mounjaro pricing data

Mounjaro, Wegovy, Ozempic, Saxenda — four names dominating the conversation around weight management in the UK right now. Here's what each one actually is, what the evidence shows, and how to think about which is appropriate for you.

Weight loss injections have moved from niche medical treatment to mainstream conversation faster than almost any pharmaceutical development in recent memory. Across the UK in 2026, prescriptions for weight loss injections have soared by more than 500%. The names — Mounjaro, Wegovy, Ozempic — appear in news coverage, social media, and everyday conversation in a way that prescription medications rarely do.

With that visibility has come significant confusion about what these medications are, how they differ, who they are appropriate for, and what the evidence actually shows. This article covers all of it.

TL;DR

• Weight loss injections are GLP-1 receptor agonists — prescription medications that mimic gut hormones to reduce appetite and slow stomach emptying.
• The three main weight loss injections currently available in the UK are tirzepatide (Mounjaro), semaglutide (Wegovy), and liraglutide (Saxenda).
• Ozempic contains the same active ingredient as Wegovy but is licensed only for type 2 diabetes — not weight loss — in the UK.
• Mounjaro produces an average weight loss of 22.5% of starting body weight at the maximum 15mg dose over 72 weeks. The gap between Mounjaro and Wegovy has narrowed significantly following MHRA approval of a 7.2mg Wegovy dose in January 2026, which achieved average weight loss of 20.7%.
• Both medications require ongoing use — most people regain significant weight within 12 months of stopping.
• Neither is a quick fix. Both work best alongside lifestyle change.

What Weight Loss Injections Actually Are

Weight loss injections belong to a class of drugs called GLP-1 receptor agonists — glucagon-like peptide-1. GLP-1 is a hormone naturally produced in the gut after eating. It signals to the brain that you are full, slows the rate at which the stomach empties, and reduces the urge to eat between meals.

GLP-1 medications mimic this hormone at higher concentrations and for longer durations than the body produces naturally, producing a sustained reduction in appetite and caloric intake. The result for most people is meaningfully reduced hunger, fewer food cravings, and consistent weight loss over weeks and months.

These are not appetite suppressants in the traditional pharmaceutical sense. They are working at a hormonal level to reset the signals that govern hunger and satiety. This is why the weight loss they produce — when they work — tends to be more consistent and sustainable than calorie-restricted diets alone, and why the side effects cluster around the gastrointestinal system.

The Four Medications: What Each One Is

Mounjaro (Tirzepatide)

Mounjaro is a dual agonist — meaning it targets two hormone receptors rather than one. By acting on both GLP-1 and GIP pathways simultaneously, tirzepatide creates a broader metabolic signal that appears to produce stronger appetite suppression and greater weight loss in most patients. GIP (glucose-dependent insulinotropic polypeptide) plays a role in metabolism and fat storage, and targeting it alongside GLP-1 appears to amplify the effects of both.

The SURMOUNT-1 trial demonstrated average weight loss of 15%, 19.5%, and 20.9% at the 5mg, 10mg, and 15mg doses respectively over 72 weeks, compared to 3.1% with placebo. At the maximum 15mg dose, Mounjaro is currently the most effective weight loss medication available in the UK.

Mounjaro is licensed in the UK for both weight management and type 2 diabetes. It is available via NHS prescription for eligible patients and on private prescription.

Wegovy (Semaglutide)

Wegovy is a GLP-1 receptor agonist — the same mechanism as Mounjaro but targeting only the GLP-1 pathway. It contains semaglutide at doses specifically approved for weight loss.

The STEP 1 trial showed participants achieved an average 14.9% weight loss over 68 weeks with semaglutide 2.4mg. A significant development in January 2026 was MHRA approval of a higher dose — 7.2mg — which the STEP UP trial found produced average weight loss of 20.7% over 72 weeks, with a third of participants losing 25% or more of their body weight.

This higher dose is not a starting dose. It is intended for people who have already reached and tolerated the 2.4mg dose but need additional support to continue losing weight or have reached a plateau.

The gap between Mounjaro and Wegovy at their respective maximum doses has now largely closed. At the 7.2mg dose, Wegovy's efficacy is essentially equivalent to Mounjaro's 15mg dose. The choice between them is now less about which produces more weight loss and more about individual tolerability, cost, and clinical suitability.

Ozempic (Semaglutide)

Ozempic contains the same active ingredient as Wegovy — semaglutide — but at a lower dose and for a different purpose. Ozempic is licensed in the UK only for the management of type 2 diabetes — not for weight loss. Its maximum dose is 2mg, compared to 2.4mg (or 7.2mg) for Wegovy.

Weight loss is a documented side effect of Ozempic, and its profile in social media and celebrity culture has driven significant demand for it as a weight loss tool. However, prescribing Ozempic off-label for weight loss when Wegovy is available is not appropriate clinical practice in the UK. If your goal is weight management, Wegovy or Mounjaro are the correct routes to explore.

Saxenda (Liraglutide)

Saxenda is an older GLP-1 medication, containing liraglutide and administered daily rather than weekly. Saxenda's side effect profile is similar to other GLP-1 medications and its results are meaningful but significantly lower than both Mounjaro and Wegovy. It may still be appropriate if you have tried newer GLP-1 medications and experienced side effects, or if your prescriber recommends it based on your medical history.

The daily injection schedule means more consistent hormone levels but less convenience than weekly alternatives. For most new patients in 2026, Saxenda is not the first-line choice.

How They Compare: The Key Data

| | Mounjaro | Wegovy | Ozempic | Saxenda |

|---|---|---|---|---|

| Active ingredient | Tirzepatide | Semaglutide | Semaglutide | Liraglutide |

| Licensed for weight loss UK | Yes | Yes | No | Yes |

| Injection frequency | Weekly | Weekly | Weekly | Daily |

| Average weight loss (max dose) | ~22.5% | ~20.7% (7.2mg) | Not licensed for this | ~5–8% |

| Max dose UK | 15mg | 7.2mg | 2mg | 3mg |

| Private cost per month | £150–£375 | £150–£295 | N/A for weight loss | Variable |

| NHS availability | Yes (criteria apply) | Yes (criteria apply) | Diabetes only | Limited |

What Happens When You Stop

This is the question most people ask after they have been on a GLP-1 medication for several months and are considering stopping.

A 2026 meta-analysis in the BMJ found that people regain a significant proportion of their lost weight within a year of stopping medication. Earlier data from the STEP-1 trial extension showed participants regained roughly two-thirds of lost weight within 12 months.

This reflects an important reality: GLP-1 medications suppress appetite pharmacologically. When the medication stops, appetite returns. Without the lifestyle changes — eating patterns, exercise habits, relationship with food — that support weight maintenance, the weight returns.

This does not make the medications ineffective. It means they work best as part of a broader programme of behavioural change rather than as a standalone intervention. The most effective outcomes in real-world data come from structured programmes that combine medication with diet coaching, exercise, and behavioural support.

NHS vs Private Access

NHS access to GLP-1 medications is managed through specialist weight management services and is based on clinical criteria. NICE guidelines in 2026 remain stringent, typically requiring a BMI over 40 and significant comorbidities for NHS coverage, with specialist weight management clinics often having waiting lists stretching into years.

Both Mounjaro and Wegovy are available on NHS prescription for eligible patients, but the criteria are strict and the pathway is slow. For most people who want to access these medications, private prescription is the practical route.

Private costs vary considerably by provider and dose:

• Mounjaro: After Eli Lilly's price adjustment in September 2025, even the starter 2.5mg dose begins at roughly £149 per month. By the time a patient reaches the 15mg maintenance dose, the monthly cost typically sits between £330 and £375.
• Wegovy: Wegovy 2.4mg is typically £150–£250 per month, making it meaningfully cheaper than Mounjaro at maintenance doses. The newer 7.2mg dose sits closer to £295 per month.

The private market for GLP-1 medications has expanded rapidly and quality varies. Always use a provider registered with the GPhC (General Pharmaceutical Council) or CQC, with GMC-registered prescribers conducting proper clinical assessments. Avoid any provider offering these medications without a full medical history review.

What's Coming: Next-Generation Options

The GLP-1 space is moving fast. Two developments worth knowing about:

Oral semaglutide: The FDA approved an oral version of Wegovy (semaglutide 25mg daily tablet) in December 2025. In clinical trials, the pill produced an average 16.6% weight loss. It is not yet available in the UK as the MHRA is still reviewing it, with approval expected towards late 2026.

Retatrutide: A next-generation injection from Eli Lilly that targets three hormone receptors (GLP-1, GIP, and glucagon) rather than the two that Mounjaro targets. The first Phase 3 trial completed in December 2025 showed average weight loss of 28.7% at 68 weeks — the highest reported for any obesity medication to date. UK approval could come in late 2026 or 2027.

Side Effects: What to Expect

The side effect profiles of Mounjaro and Wegovy are similar, reflecting their shared mechanism of action.

Most common: nausea, vomiting, constipation, diarrhoea — particularly in the early weeks of treatment and when doses are increased. Eating smaller meals, avoiding high-fat foods, and staying well hydrated helps manage these effects. They typically improve as the body adjusts.

Less common but serious: pancreatitis, gallbladder problems, and kidney problems related to dehydration. These are rare but require medical attention if they occur.

Mounjaro-specific note: Mounjaro may affect the absorption of oral medications, including the contraceptive pill. Anyone taking oral contraceptives should discuss additional contraceptive methods with their prescriber before starting Mounjaro.

Both medications should be stopped before planned pregnancy — semaglutide at least two months before, tirzepatide at least one month before.

Who These Medications Are Not For

GLP-1 medications are not appropriate for everyone. They should not be used by people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, or during pregnancy or breastfeeding. People with a history of pancreatitis, severe gastrointestinal conditions, or eating disorders should discuss these carefully with a clinician before starting.

These medications also carry a risk of muscle loss alongside fat loss, particularly when weight loss is rapid. Adequate protein intake and resistance exercise are important throughout treatment to preserve lean mass.

Frequently Asked Questions

What is the most effective weight loss injection in the UK in 2026?

Based on clinical trial data, Mounjaro (tirzepatide) at its maximum 15mg dose produces the highest average weight loss — approximately 22.5% of starting body weight over 72 weeks. However, Wegovy's new 7.2mg dose, approved in January 2026, achieved average weight loss of 20.7% — narrowing the gap considerably. The most effective medication for any individual depends on tolerability, medical history, and cost as much as headline trial data.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide, but at different doses and for different purposes. Wegovy is licensed in the UK for weight management at doses up to 7.2mg. Ozempic is licensed only for type 2 diabetes at a maximum of 2mg. Ozempic is not approved for weight loss in the UK and should not be used off-label for this purpose when Wegovy is available.

How much do weight loss injections cost in the UK?

Private costs vary by medication and dose. Mounjaro ranges from approximately £149 per month at the starter dose to £330–£375 at the maximum 15mg dose. Wegovy at 2.4mg typically costs £150–£250 per month, rising to around £295 for the new 7.2mg dose. NHS access is available for both but requires meeting strict clinical criteria through specialist weight management services.

Will I regain weight when I stop taking weight loss injections?

Most people regain a significant proportion of lost weight within 12 months of stopping GLP-1 medication. A 2026 BMJ meta-analysis and earlier STEP-1 trial data both show approximately two-thirds of lost weight is regained within a year of stopping without sustained lifestyle changes. This is why these medications work best as part of a broader programme that includes dietary and behavioural support.

Can I get weight loss injections on the NHS?

Yes — both Mounjaro and Wegovy are available on NHS prescription, but criteria are stringent. NHS guidelines typically require a BMI over 40 with significant comorbidities, and access is through specialist weight management services which often have long waiting lists. Most people access these medications via private prescription.

Are weight loss injections safe long-term?

Both Mounjaro and Wegovy have been studied in large, long-term clinical trials and have well-characterised safety profiles. Common side effects are gastrointestinal and typically improve over time. Serious side effects are rare. The long-term safety picture continues to develop as more real-world data accumulates. These medications must be prescribed and monitored by a healthcare professional — they are not suitable for self-administration without clinical oversight.

The Bottom Line

Weight loss injections represent a genuine and significant advance in obesity treatment. The evidence for Mounjaro and Wegovy is robust, the mechanisms are well understood, and for people with obesity-related health conditions, the clinical benefits can be substantial.

They are not magic. They work best alongside meaningful lifestyle change — and most people who stop them without that foundation regain the weight they lost. The decision to start one of these medications should involve a proper clinical assessment, realistic expectations, and a plan for what happens beyond the medication itself.

If you are looking at how to support your overall health while on or considering these medications, the Gut Reset and Sugar Reset from the Reset Series™ cover the dietary foundations that support the lifestyle changes these medications work best alongside.

Related reading: GLP-1 Drugs and Liver Health: What the Research Shows · BMI and Weight Loss Injection Eligibility · Ultra-Processed Foods and Heart Disease Risk

Popular Articles